Highlights

  • Emyria reported approximately A$1.42 million in quarterly revenue, compared with A$0.47 million a year earlier, as its Empax network expanded.
  • The company opened its first Sydney clinic in September and increased national treatment beds to eighteen across four states.
  • Emyria received initial eligible veterans’ funding approvals after quarter-end, while screening and applications continue for more than forty referrals nationally.
  • Cash declined to A$4.745 million after A$2.282 million operating outflow, with no loan facilities and no new funding announced.

Record revenue accompanied a wider treatment network at Emyria Limited (ASX:EMD), while the September 2026 quarter also consumed cash. Revenue reached approximately A$1.42 million, up from A$0.47 million a year earlier, as the first Sydney Empax clinic opened. Closing cash fell to A$4.745 million, leaving a company-estimated funding period of about 2.08 quarters at the latest operating outflow rate.

Network Expansion Adds Treatment Capacity

Emyria delivers psychedelic-assisted therapy through its Empax brand using Authorised Prescribers. The report concerns treatment delivery and contains no clinical trial results.

The Sydney clinic opened on schedule in September. Initial patients there have received funding under the New South Wales workers’ compensation scheme.

A Mornington Peninsula clinic opened in late May, with a second Authorised Prescriber expected to join during the December quarter. Perth added two prescribers, providing weekday coverage, and trained another 15 therapists.

Further Perth recruitment and training are expected in November, with higher throughput anticipated from the first quarter of 2027. Brisbane prescriber availability was inconsistent, although three new practitioners began onboarding late in the period.

National treatment beds rose from 14 to 18. Emyria says that capacity supports up to 90 dosing sessions weekly across four states; it is a capacity measure rather than reported completed treatment volume.

Funding Approvals Precede Patient Treatments

Initial eligible patient approvals from the Department of Veterans’ Affairs arrived after quarter-end. More than 40 referrals have been received nationally, with screening and funding applications progressing.

No treatment dates are given; approvals remain distinct from delivered care or recognised revenue.

Executive Chair Greg Hutchinson presented the company’s real-world treatment experience at an FDA public hearing on 14 September. Former US Secretary of Veterans Affairs Dr David Shulkin was appointed strategic adviser for US partnerships and commercial opportunities.

Emyria is also in late-stage discussions with an international pharmaceutical sponsor for the second participant in its Empax Global Partnership Program. No agreement has been signed, and further information is expected next quarter.

Workforce Investment Increases Cash Requirements

Customer receipts totalled A$1.597 million. Operating cash outflow was A$2.282 million, including A$1.166 million in staff costs, A$1.319 million in product manufacturing and operations, and A$1 million in administration.

The company attributes part of the outflow to workforce readiness and larger minimum medication reserves for Sydney. Approximately A$725,000 of earned revenue had not been received as cash at quarter-end.

Cash declined from A$7.290 million in June to A$4.745 million. No loan or standby facilities were available, and no new funding was announced.

The 2.08-quarter estimate assumes operating outflow remains at the latest rate. Cash receipt timing, prescriber availability and funding approvals continue to affect the operating position. Near-term milestones include Victorian onboarding, further Perth recruitment and more consistent Brisbane dosing through the December quarter and early 2027.